Finanzen von Novocure Ltd (NVCR)NVCRNovocure Ltd

Evaluating the bottom line, NovoCure Limited maintains a gross margin of 77.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.75%, while the net margin is -8.53%. These profitability ratios, combined with a Return on Equity (ROE) of -43.22%, provide a clear picture of how effectively NVCR converts its operational activities into shareholder value.

In the context of the broader market, NVCR competes directly with industry leaders such as ESTA and XRAY. With a market capitalization of $2.06B, it holds a significant position in the sector. When comparing efficiency, NVCR's gross margin of 77.61% stands against ESTA's 70.64% and XRAY's 54.90%. Such benchmarking helps identify whether NovoCure Limited is trading at a premium or discount relative to its financial performance.

Novocure's Q2 2026 revenue of $183.6 million was a 16% increase year-over-year, and the gross margin stands at 77.61%. Despite this, the company continues to report negative net income, with a loss of -$15.66 million in Q2 2026.